WO2017007142A1 - Cosmetic composition for alleviating skin aging or skin wrinkles, containing malva verticillata seed extract - Google Patents

Cosmetic composition for alleviating skin aging or skin wrinkles, containing malva verticillata seed extract Download PDF

Info

Publication number
WO2017007142A1
WO2017007142A1 PCT/KR2016/006358 KR2016006358W WO2017007142A1 WO 2017007142 A1 WO2017007142 A1 WO 2017007142A1 KR 2016006358 W KR2016006358 W KR 2016006358W WO 2017007142 A1 WO2017007142 A1 WO 2017007142A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
extract
cosmetic composition
lotion
skin aging
Prior art date
Application number
PCT/KR2016/006358
Other languages
French (fr)
Korean (ko)
Inventor
박지은
남진주
노윤화
김연준
Original Assignee
코스맥스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스 주식회사 filed Critical 코스맥스 주식회사
Publication of WO2017007142A1 publication Critical patent/WO2017007142A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Definitions

  • Cosmetic composition for skin aging or wrinkle improvement containing copper sperm extract containing copper sperm extract
  • the present invention has been made by the task number 10046945 under the support of the Republic of Korea Small and Medium Business Administration, the research management specialized agency of the project is Korea Industrial Technology Promotion Agency, the research project name is "World Class 300 Project R & D”, the research project name is "K-Cosmetic leading functional Development of skin cell receptor-regulated functional new materials and development of optimal skin delivery technology containing them ", The host organization is Cosmax Co., Ltd., and the research period is 2013.09.01 ⁇ 2017.08.31.
  • the present invention relates to a skin composition for improving skin aging or wrinkles, and more particularly to a cosmetic composition for improving skin aging or wrinkles containing a copper sperm extract.
  • the skin is the outermost organ of the body, protecting our bodies from the outside environment. However, the skin is exposed to external stimuli more easily than other organs, so it is easily attacked. In particular, the skin of the face is directly exposed to ultraviolet rays and pollutants, and thus has a characteristic of premature aging.
  • MMPs matrix metal loproteinases
  • 11 ⁇ -HSD1 is an enzyme that converts cortisol, a stress hormone, from inactivated cortisone to activated cortisol, and is distributed in the epidermis and dermis. It was found that the expression increased significantly. In other words, it is not only stress reaction caused by various internal mental factors but also activity and expression is increased by external factors such as ultraviolet rays, air pollutants and chemicals. have.
  • Wrinkle improvement material has been mainly used in cosmetics and medicines, such as vitamin C, a-tocope, retinol and derivatives thereof, but when they are formulated in the formulation, there is a bad smell or poor chemical stability There are disadvantages.
  • the present inventors have diligently researched to overcome the problems of the prior art, in the case of a cosmetic composition for improving skin aging or wrinkles containing Donggyuja extract as an active ingredient, by inhibiting ⁇ -HSDl and MMP-1 It was confirmed that it can exhibit the skin aging or skin aging effect, and completed the present invention.
  • the main object of the present invention is to provide a cosmetic composition for improving skin aging or wrinkles containing Donggyuja extract having skin aging or skin improvement effect by inhibiting ⁇ -HSDl and MMP-1.
  • the present invention provides a cosmetic composition for improving skin aging or wrinkles, which contains an extract of Donggyuja as an active ingredient.
  • the sperm extract may be extracted with any solvent used in the prior art, preferably extracted with water, hydrophilic oil-soluble solvents or their mixed solvents, more preferably water, anhydrous or water And methanol, ethane, propyl alcohol, butyl alcohol, glycerin, propylene glycol, butylene glycol, or one or more solvents selected from the group consisting of a mixed solvent thereof. All of them have a hydrophilic alcohol group (0 ⁇ ), which shows similar polarity, and thus can exhibit similar extraction activity for solutes.
  • the sperm extract is characterized in that it comprises 0.01 to 50% by weight relative to the total weight of the composition. If it is outside the above range, the formulation is not available and is not preferable.
  • the sperm extract is ll
  • the sperm extract of the present invention inhibits ⁇ -HSDl increased by UVB. From these results, it can be seen that the sperm extract of the present invention can improve skin aging by relieving stress in the skin by inhibiting ⁇ -HSDl (see Experimental Example 2-3).
  • the sperm extract is characterized by exhibiting an anti-wrinkle effect by inhibiting MMP-1 (Matr ix metal loproteinase-1).
  • the sperm extract of the present invention inhibits MMP-1 increased by UVB. From these results, it can be seen that the sperm extract of the present invention can improve wrinkles by inhibiting the degradation of skin proteins such as collagen by inhibiting MMP-1 (see Experimental Example 1).
  • the sperm extract is characterized by exhibiting skin aging or wrinkle improvement effect by increasing the expression of procol lagen type I.
  • the content of procol lagen type I in the group irradiated with UVB on the artificial culture skin was decreased, whereas the content of procol lagen type I in the group treated with the extract of the present invention on the artificial culture skin irradiated with UVB. This increase was confirmed. From these results, it can be seen that the sperm extract of the present invention can improve skin aging or wrinkles by increasing the expression of procol lagen type I (see Experimental Example 4).
  • the composition is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack At least one formulation selected from the group consisting of soaps, cleansing products, cleansing lotions, cleansing creams, body lotions and body cleansers.
  • the dongjaja extract of the present invention as an active ingredient Containing cosmetic composition exhibits excellent effects in relieving stress in the skin and improving aging and wrinkles by effectively suppressing the expression of ⁇ -HSDl and MMP overexpressed by ultraviolet rays.
  • 1 is a view showing the results of experiments confirming the MMP-1 inhibitory activity of Donggyuja extract.
  • Figure 2 is a view showing the results of experiments confirming the inhibitory ability of ⁇ -HSDl of sperm extract.
  • Figure 3 is a diagram showing the results of experiments confirming the MMP-1 inhibitory ability of Donggyuja extract in artificial culture skin.
  • Figure 4 is a view showing the experimental results confirming the procol lagen type I increase ability of Donggyuja extract in artificial culture skin.
  • Donggyu used in the present invention was used to buy from the ⁇ ⁇ ⁇ Oriental medicine of the Republic of Korea.
  • MMP-1 inhibitory effect of the sperm extract of Example 1 the expression level of MMP-1 in human fibroblast cell line (Human dermal f ibroblast, Hs68) was measured.
  • Human fibroblasts were dispensed into 6wel l plates by the number of 4X10, and then cultured for 24 hours in an incubator at 37 ° C, 5% C0 2 conditions. After removing the medium and putting DPBS, irradiated with 15mJ / cm 2 of UVB to the remaining cell group except the UVB non-irradiated group was added to each concentration of incubation culture and further incubated for 24 hours. Then, RA was isolated from the cells of each sample by using trizol (RNA iso, DAKARA, Japan), quantified RNA at 260 nm using nanodrop, and then synthesized cDNA in an amplifier using each ig RNA. (C1000 Thermal Cycler, Bio-Rad, USA).
  • the target protein in the synthesized cDNA MMP-1 template (primer) and a cyanine dye, SYBR Green (SYBR Green superrais, Appl ied Biosystems , USA) using a common compound added chain real-time polymerase in real ⁇ t ime PCR machine
  • SYBR Green SYBR Green superrais, Appl ied Biosystems , USA
  • EpiDermFT TM containing both epidermis and dermis was first stabilized in the culture medium for 24 hours, and then the medium was removed, and 60 mJ / cm 2 of UVB was irradiated to the remaining experimental groups except for the non-UVB irradiated group, and sperm extract was added by concentration Alternate with one medium and incubate further for 48 hours. Then, the culture medium obtained by culturing artificial skin tissue was collected and used to measure the amount of protein contained in the medium by removing suspended solids by centrifugation. The amount of MMP-1 protein contained in the culture medium was measured by the guided method using MMP-1 ELISA Ki t (EMD Mill ipore, USA).
  • the toner agent containing the extract obtained in Example 1 was prepared in the usual manner according to the composition components and composition ratios shown in Table 2 below.
  • Cream containing the extract obtained in Example 1 was prepared according to the conventional method according to the composition and composition ratio shown below.
  • Patent Document 0001 KR 10-0825256 B
  • Patent Document 0002 KR 10-1393007 B

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a cosmetic composition for alleviating skin aging or skin wrinkles, containing a Malva verticillata seed extract. According to the present invention, the cosmetic composition containing a Malva verticillata seed extract as an active ingredient can exhibit an effect of alleviating skin aging or improving the skin by inhibiting 11β-HSD1 and MMP-1.

Description

【명세서】  【Specification】
【발명의 명칭】 [Name of invention]
동규자 추출물을 함유하는 피부노화 또는 피부주름 개선용 화장료 조성물 【기술분야】  Cosmetic composition for skin aging or wrinkle improvement containing copper sperm extract
본 발명은 대한민국 중소기업청 지원하에 과제번호 10046945에 의해 이루어진 것으로서, 상기 과제의 연구관리전문기관은 한국산업기술진홍원, 연구사업명은 "World Class 300 프로젝트 R&D" , 연구과제명은 "K-Cosmet ic 선도형 기능성 화장품용 피부세포 수용체 조절 기능성 신소재 발굴 및 이를 함유한 최적 피부전달기술 개발" , 주관기관은 코스맥스 (주), 연구기간은 2013.09.01 ~ 2017.08.31이다.  The present invention has been made by the task number 10046945 under the support of the Republic of Korea Small and Medium Business Administration, the research management specialized agency of the project is Korea Industrial Technology Promotion Agency, the research project name is "World Class 300 Project R & D", the research project name is "K-Cosmetic leading functional Development of skin cell receptor-regulated functional new materials and development of optimal skin delivery technology containing them ", The host organization is Cosmax Co., Ltd., and the research period is 2013.09.01 ~ 2017.08.31.
본 발명은 피부노화 또는 피부주름 개선용 화장료 조성물에 관한 것으로, 더욱 구체적으로 동규자 추출물을 함유하는 피부노화 또는 피부주름 개선용 화장료조성물 관한 것이다.  The present invention relates to a skin composition for improving skin aging or wrinkles, and more particularly to a cosmetic composition for improving skin aging or wrinkles containing a copper sperm extract.
【배경기술】 Background Art
피부는 신체의 가장 바깥에 존재하는 기관으로, 외부 환경으로부터 우리 몸을보호하는 역할을수행한다. 그러나피부는 다른 기관들에 비해 외부 자극에 많이 노출되어 있어 쉽게 공격받을 수 있고, 특히 그 중에서도 얼굴 피부의 경우에는 자외선 및 공해 물질 등에 직접적으로 노출되어 있어 조기에 노화가 발생하기 쉬운 특징을 갖는다.  The skin is the outermost organ of the body, protecting our bodies from the outside environment. However, the skin is exposed to external stimuli more easily than other organs, so it is easily attacked. In particular, the skin of the face is directly exposed to ultraviolet rays and pollutants, and thus has a characteristic of premature aging.
자외선, 대기 오염, 스트레스나 질병, 흡연 등에 의해 피부에서 나타나는 주름, 탄력 감소, 피부 쳐짐 및 건조 현상 등은 대부분 세포외기질 (extracel lular matrix) 단백질의 변화로 인해 발생하는 현상으로써, 주로 진피층에 존재하는 결합조직인 콜라겐, 엘라스틴, 히아루론산 등의 파괴가 원인으로 지목된다. 특히 이 중에서도 matrix metal loproteinases(MMPs)가 기질단백질을 분해하는 대표적인 효소로 알려져 있다. MMP는 단 한 번의 자외선 조사에 의해서도 그 활성이 현저히 증가되어 콜라겐을 비롯한 여러 기질단백질을 분해함으로써 주름 형성을 가속화한다. Wrinkles, decreased elasticity, skin sagging, and dryness caused by UV rays, air pollution, stress, illness, and smoking are mostly caused by changes in the extracelular matrix protein. The collagen, elastin, and hyaluronic acid, which are connective tissues, are considered to be the cause. In particular, matrix metal loproteinases (MMPs) are known as representative enzymes that degrade substrate proteins. MMP only one UV Irradiation also significantly increases its activity, accelerating wrinkle formation by degrading collagen and other matrix proteins.
이러한 자외선 노출에 의한 피부 조직의 변화에 대해 최근 새로운 인자가 주목받기 시작하였는데, Skobowiat 등의 연구에서 11β -hydroxysteroid dehydrogenase type Κΐΐβ -HSDI)이 자외선에 의한 스트레스 조절에서 핵심 역할을 수행함을 확인하였다 (Skobowiat C et al , 2013; 168(3) : 595-601) . 11β - HSD1은 스트레스 호르몬의 일종인 코르티솔 (cost i sol )을 비활성화 상태인 코르티손 (cort ison)에서 활성화상태인 코르티솔로 전환시키는 효소로써 표피와 진피에 분포하고 있는데, 자외선 조사, 특히 UVB에 의해 그 발현이 현저히 증가함이 밝혀졌다. 즉 내부의 다양한 정신적인 요인에 의한 스트레스 반웅뿐만 아니라외부 요인인 자외선, 대기 오염물질, 화학물질 등에 의해 활성 및 발현이 증가되는 물질로 피부에서의 스트레스 반웅과 밀접하게 관련되어 있어 새로운 타겟으로주목받고 있다.  A new factor has recently attracted attention for changes in skin tissues caused by UV exposure, and studies by Skobowiat et al. Confirmed that 11β-hydroxysteroid dehydrogenase type Κΐΐβ -HSDI plays a key role in the regulation of UV-induced stress. C et al, 2013; 168 (3): 595-601). 11β-HSD1 is an enzyme that converts cortisol, a stress hormone, from inactivated cortisone to activated cortisol, and is distributed in the epidermis and dermis. It was found that the expression increased significantly. In other words, it is not only stress reaction caused by various internal mental factors but also activity and expression is increased by external factors such as ultraviolet rays, air pollutants and chemicals. have.
그동안 주름개선을 위한 소재로는 주로 비타민 C, a -토코페를, 레티놀 및 그의 유도체 등이 화장품 및 의약품에 배합되어 이용되어 왔으나 이들은 제형에 배합되었을 경우 변취 현상이 발생하거나 화학적 안정성이 좋지 못하다는 단점이 있다.  Wrinkle improvement material has been mainly used in cosmetics and medicines, such as vitamin C, a-tocope, retinol and derivatives thereof, but when they are formulated in the formulation, there is a bad smell or poor chemical stability There are disadvantages.
이러한 단점을 극복하기 위해 최근 천연물 유래 물질들을 이용한 주름개선용 화장료조성물의 개발이 각광받고 있으며 이의 발굴을 필요로 한다. 동규자 (Malva vert ici l lata L. Seed)는무궁화과식물인 아욱의 여문씨를 말린 것으로 냄새는 거의 없고 부드럽고 기름기가 있으며, 맛은 달고 성질은 차다. 방광경에 작용하여 임증, 부종, 배뇨 장애, 변비, 젖의 분비가 부족한증, 노인이나허한사람들에 전통적으로사용되어 왔음이 알려져 있다.  In order to overcome these disadvantages, the development of cosmetic compositions for improving wrinkles using natural-derived materials are in the limelight and require the excavation thereof. Malva vert ici l lata L. Seed is a dried dried Mallow larva seed, a odorless, soft and greasy, sweet and cold. It is known to work on the cystoscope, it has been traditionally used in pregnancy, swelling, urination disorders, constipation, lack of lactation, the elderly and people with disabilities.
종래에 다양한 천연물 유래 물질들을 이용한 피부노화 또는 주름개선용 화장료 조성물들에 대해서 많이 연구되어 왔으나, 본원발명의 동규자 추출물의 피부노화또는주름개선 효과에 대해서는 아직 알려진바 없다.  In the past, many studies have been made on skin aging or anti-wrinkle cosmetic compositions using various natural substances, but the effect of aging on the skin aging or wrinkle improvement of the present invention is not known.
이에, 본 발명자들은 상기 종래기술들의 문제점들을극복하기 위하여 예의 연구노력한 결과, 동규자 추출물을 유효성분으로 함유하는 피부노화 또는 피부주름 개선용 화장료 조성물의 경우, ΙΙβ -HSDl 및 MMP-1을 억제함으로써 피부노화또는 피부개션 효과를 나타낼 수 있음을 확인하고, 본 발명을 완성하게 되었다. Accordingly, the present inventors have diligently researched to overcome the problems of the prior art, in the case of a cosmetic composition for improving skin aging or wrinkles containing Donggyuja extract as an active ingredient, by inhibiting Ιβ-HSDl and MMP-1 It was confirmed that it can exhibit the skin aging or skin aging effect, and completed the present invention.
【발명의 상세한설명】 Detailed Description of the Invention
【기술적 과제】  [Technical problem]
따라서, 본 발명의 주된 목적은 ΙΙβ -HSDl 및 MMP-1을 억제함으로써 피부노화 또는 피부개선 효과를 갖는 동규자 추출물을 함유하는 피부노화 또는 피부주름 개선용화장료조성물을 제공하는 데 있다.  Therefore, the main object of the present invention is to provide a cosmetic composition for improving skin aging or wrinkles containing Donggyuja extract having skin aging or skin improvement effect by inhibiting ΙΙβ -HSDl and MMP-1.
【기술적 해결방법】 Technical Solution
본 발명의 한 양태에 따르면, 본 발명은 동규자 추출물을 유효성분으로 함유하는피부노화또는주름 개선용 화장료조성물을 제공한다.  According to one aspect of the present invention, the present invention provides a cosmetic composition for improving skin aging or wrinkles, which contains an extract of Donggyuja as an active ingredient.
종래에 주름 개선을 위한소재로는 주로 비타민 (:, α -토코페를, 레티놀 및 그의 유도체 등이 화장품 및 의약품에 배합되어 이용되어 왔으나 이들은 제형에 배합되었을 경우 변취 현상이 발생하거나 화학적 안정성이 좋지 못하다는단점이 있다. 이에 본 발명자들이 주름 개선을 위한 소재로 천연물 유래 물질들을 발굴하기 위하여 연구노력한 결과, 본원발명의 동규자 추출물이 주름 개선 효과가 있는 것을 확인하고 본 발명을 완성하게 되었다. Conventionally, as a material for improving wrinkles, vitamins ( :, α-tocope, retinol and derivatives thereof have been used in cosmetics and medicines, but when they are formulated in the formulation, bad odor or chemical stability is poor. As a result of the present inventors' efforts to discover natural substances derived from the material for improving wrinkles, the present inventors confirmed that the extract of the present invention has an effect of improving wrinkles and completed the present invention.
본 발명에 있어서, 상기 동규자 추출물은 종래에 사용되어진 어떠한 용매로도 추출될 수 있으며, 바람직하게는 물, 친수성 유가용매 또는 이들의 흔합용매로추출될 수 있으며, 더욱 바람직하게는 물, 무수 또는 함수의 메탄올, 에탄을, 프로필 알코을, 부틸 알코을, 글리세린, 프로필렌 글리콜, 부틸렌 글리콜, 또는 이들의 흔합용매로 구성된 군으로부터 선택된 하나 이상의 용매로 추출된 것을 특징으로 한다. 이들은 모두 친수성 알콜기 (0Η)를 가지고 있어서 유사한극성을 나타내므로용질에 대한 비슷한추출활성을나타낼 수 있다.  In the present invention, the sperm extract may be extracted with any solvent used in the prior art, preferably extracted with water, hydrophilic oil-soluble solvents or their mixed solvents, more preferably water, anhydrous or water And methanol, ethane, propyl alcohol, butyl alcohol, glycerin, propylene glycol, butylene glycol, or one or more solvents selected from the group consisting of a mixed solvent thereof. All of them have a hydrophilic alcohol group (0Η), which shows similar polarity, and thus can exhibit similar extraction activity for solutes.
본 발명에 있어서, 상기 동규자 추출물은 조성물 총 중량 대비 0.01 내지 50 중량 % 포함하는 것을 특징으로 한다. 상기 범위를 벗어나는 경우에는 제형화가용이하지 않아바람직하지 못하다.  In the present invention, the sperm extract is characterized in that it comprises 0.01 to 50% by weight relative to the total weight of the composition. If it is outside the above range, the formulation is not available and is not preferable.
본 발명에 있어서, 상기 동규자 추출물은 ll|3 -HSDl( lli3 -hydn)xysteroid dehydrogenase type 1)을 억제함으로써 피부노화개선 효과를 나타내는 것을 특징으로 한다. In the present invention, the sperm extract is ll | 3 -HSDl (lli3 -hydn) xysteroid By suppressing dehydrogenase type 1) is characterized in that the skin aging improvement effect.
본 발명의 실험예에 따르면, 본원발명의 동규자 추출물이 UVB에 의하여 증가된 ΙΙβ -HSDl를 억제하는 것을 확인할 수 있었다. 이러한 결과로 볼 때, 본원발명의 동규자 추출물이 ΙΙβ -HSDl를 억제함으로써 피부에서의 스트레스를 완화하여 피부노화를 개선할수 있다는 것을 알수 있다 (실험예 2-3 참조) .  According to the experimental example of the present invention, it was confirmed that the sperm extract of the present invention inhibits ΙΙβ -HSDl increased by UVB. From these results, it can be seen that the sperm extract of the present invention can improve skin aging by relieving stress in the skin by inhibiting ΙΙβ-HSDl (see Experimental Example 2-3).
본 발명에 있어서, 상기 동규자 추출물은 MMP-l(Matr ix metal loproteinase-1)을 억제함으로써 주름 개선 효과를 나타내는 것을 특징으로 한다.  In the present invention, the sperm extract is characterized by exhibiting an anti-wrinkle effect by inhibiting MMP-1 (Matr ix metal loproteinase-1).
본 발명의 실험예에 따르면, 본원발명의 동규자 추출물이 UVB에 의하여 증가된 MMP-1를 억제하는 것을 확인할 수 있었다. 이러한 결과로 볼 때, 본원발명의 동규자추출물이 MMP-1를 억제함으로써 콜라겐과 같은 피부 단백질의 분해를 막아주름을 개선할수 있다는 것을 알수 있다 (실험예 1 참조) .  According to the experimental example of the present invention, it was confirmed that the sperm extract of the present invention inhibits MMP-1 increased by UVB. From these results, it can be seen that the sperm extract of the present invention can improve wrinkles by inhibiting the degradation of skin proteins such as collagen by inhibiting MMP-1 (see Experimental Example 1).
본 발명에 있어서, 상기 동규자 추출물은 procol lagen type I의 발현을 증가시킴으로써 피부노화또는주름개선 효과를 나타내는 것을 특징으로 한다. 본 발명의 실험예에 따르면, 인공배양피부에 UVB를 조사한 군에서 procol lagen type I 의 함량이 감소한 반면에 UVB를 조사한 인공배양피부에 본원발명의 동규자 추출물을 처리한 군에서는 procol lagen type I의 함량이 증가한 것을 확인할 수 있었다. 이러한 결과로 볼 때, 본원발명의 동규자 추출물이 procol lagen type I의 발현을 증가시킴으로써 피부노화 또는 주름을 개선할수 있다는 것을 알수 있다 (실험예 4 참조) .  In the present invention, the sperm extract is characterized by exhibiting skin aging or wrinkle improvement effect by increasing the expression of procol lagen type I. According to the experimental example of the present invention, the content of procol lagen type I in the group irradiated with UVB on the artificial culture skin was decreased, whereas the content of procol lagen type I in the group treated with the extract of the present invention on the artificial culture skin irradiated with UVB. This increase was confirmed. From these results, it can be seen that the sperm extract of the present invention can improve skin aging or wrinkles by increasing the expression of procol lagen type I (see Experimental Example 4).
본 발명에 있어서, 상기 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림 , 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징품, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 구성된 제형에서 선택된 하나 이상의 제형인 것을특징으로 한다.  In the present invention, the composition is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack At least one formulation selected from the group consisting of soaps, cleansing products, cleansing lotions, cleansing creams, body lotions and body cleansers.
【유리한효과】 Advantageous Effects
이상 설명한 바와 같이, 본 발명의 동규자 추출물을 유효성분으로 함유하는 화장료 조성물은 자외선에 의해 과발현된 ΙΙβ -HSDl 및 MMP의 발현을 효과적으로 억제시킴으로써 피부에서의 스트레스를 완화하고 노화 및 주름을 개선하는 데 우수한효과를 나타낸다. As described above, the dongjaja extract of the present invention as an active ingredient Containing cosmetic composition exhibits excellent effects in relieving stress in the skin and improving aging and wrinkles by effectively suppressing the expression of Ιββ-HSDl and MMP overexpressed by ultraviolet rays.
【도면의 간단한설명】 【Brief Description of Drawings】
도 1은 동규자 추출물의 MMP-1 저해능을 확인한 실험 결과를 나타내는 도면이다.  1 is a view showing the results of experiments confirming the MMP-1 inhibitory activity of Donggyuja extract.
도 2는동규자추출물의 ΙΙβ -HSDl 저해능을 확인한실험 결과를 나타내는 도면이다.  Figure 2 is a view showing the results of experiments confirming the inhibitory ability of ΙΙβ -HSDl of sperm extract.
도 3은 인공배양피부에서 동규자 추출물의 MMP-1 저해능을 확인한 실험 결과를 나타내는 도면이다.  Figure 3 is a diagram showing the results of experiments confirming the MMP-1 inhibitory ability of Donggyuja extract in artificial culture skin.
도 4는 인공배양피부에서 동규자 추출물의 procol lagen type I 증가능을 확인한실험 결과를 나타내는도면이다.  Figure 4 is a view showing the experimental results confirming the procol lagen type I increase ability of Donggyuja extract in artificial culture skin.
【발명의 실시를 위한 형태】 [Form for implementation of invention]
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다. 실시예 1: 동규자추출물의 제조  Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only intended to illustrate the invention, and the scope of the invention is not to be construed as limited by these examples. Example 1 Preparation of Copper Enamel Extract
본 발명에서 사용된 동규자는 대한민국의 ^동의한방에서 구입하여 사용하였다.  Donggyu used in the present invention was used to buy from the ^ 의 ^ Oriental medicine of the Republic of Korea.
동규자 100g을 취하여 별개의 용기에 넣고, 추출용매로서 70중량 % 에탄을 수용액 1L에 침적하여 72시간 동안 실온에 방치하여 추출액을 얻었다. 얻어진 추출액을 여과지를 이용하여 여과한 다음, 여액을 회전식 증발 건조기로 감압 농축하여 10.0%의 추출물을 얻었다. 상기의 얻어진 추출 흔합물을 용해제로서 DMS0(Dimethyl sul foxide)에 1 mg/ml 및 10 mg/ml의 농도로 용해시켜 이하의 실험예에 사용하였다. 실험예 1: 동규자추출물의 MMP-1 저해능평가 100 g of copper ruler was taken and placed in a separate container. 70 wt% ethane was immersed in 1 L of an aqueous solution as an extraction solvent and left at room temperature for 72 hours to obtain an extract. The obtained extract was filtered using filter paper, and the filtrate was concentrated under reduced pressure with a rotary evaporator to obtain an extract of 10.0%. The obtained extract mixture was dissolved in DMS0 (dimethyl sul foxide) at a concentration of 1 mg / ml and 10 mg / ml as a solubilizer, and used in the following experimental example. Experimental Example 1 Evaluation of MMP-1 Inhibitory Activity of Copper Fructus Extract
실시예 1의 동규자 추출물의 MMP-1 저해 효과를 평가하기 위해 사람의 섬유아세포 세포주 (Human dermal f ibroblast , Hs68)에서의 MMP-1 발현량을 측정하였다.  In order to evaluate the MMP-1 inhibitory effect of the sperm extract of Example 1, the expression level of MMP-1 in human fibroblast cell line (Human dermal f ibroblast, Hs68) was measured.
사람섬유아세포를 6wel l plate에 4X10의 수만큼 분주한후, 37°C, 5% C02 조건의 배양기에서 24시간 동안 배양하였다. 이후 배지를 제거하고 DPBS를 넣어준 후 UVB 비조사군을 제외한 나머지 세포군에 15mJ/cm2의 UVB를 조사한 뒤 동규자 추출물을 농도별로 첨가하여 24시간 동안 추가로 배양하였다. 그 후 각 샘플의 세포에서 트리졸 (RNA iso , DAKARA, 일본)을 이용하여 R A를 분리한 뒤 nanodrop을 이용하여 260nm에서 RNA를 정량한 후, 각각 ig의 RNA를 사용하여 증폭기에서 cDNA를 합성하였다 (C1000 Thermal Cycler , Bio-Rad, 미국) . 합성된 cDNA에 타겟 단백질인 MMP-1 주형 (primer)과 시아닌 염료인 사이버그린 (SYBR Green superrais , Appl ied Biosystems , 미국)을 첨가한 흔합물을 이용하여 real¬ t ime PCR 기계에서 실시간 중합효소 연쇄반웅을 실시함으로써 최종적으로 MMP-1 유전자의 발현 정도를 평가하였다. 주형의 서열과 반웅 조건은 하기의 표 1과 같았으며, 유전자의 발현량은 β -act in 유전자에 대한 보정을 통해 최종적으로 분석하였다. 이에 대한결과는도 1에 나타내었다. Human fibroblasts were dispensed into 6wel l plates by the number of 4X10, and then cultured for 24 hours in an incubator at 37 ° C, 5% C0 2 conditions. After removing the medium and putting DPBS, irradiated with 15mJ / cm 2 of UVB to the remaining cell group except the UVB non-irradiated group was added to each concentration of incubation culture and further incubated for 24 hours. Then, RA was isolated from the cells of each sample by using trizol (RNA iso, DAKARA, Japan), quantified RNA at 260 nm using nanodrop, and then synthesized cDNA in an amplifier using each ig RNA. (C1000 Thermal Cycler, Bio-Rad, USA). The target protein in the synthesized cDNA MMP-1 template (primer) and a cyanine dye, SYBR Green (SYBR Green superrais, Appl ied Biosystems , USA) using a common compound added chain real-time polymerase in real ¬ t ime PCR machine Finally, the expression level of the MMP-1 gene was evaluated. The sequence and reaction conditions of the template were as shown in Table 1 below, and the expression level of the gene was finally analyzed through correction for the β-act in gene. The results are shown in FIG. 1.
【표 1】 Table 1
Figure imgf000007_0001
그 결과, 도면 1에 나타낸 바와 같이 UVB 조사군에서 MMP-1 발현량이 증가한 것에 반해, 동규자 추출물 처리군에서 농도 의존적으로 MMP-1 유전자 발현량이 감소함을 확인하였다. 실험예 2: 동규자추출물의 ΙΙ β -HSDl저해능 평가 실시예 1의 동규자추출물의 ΙΙβ -HSDl 저해 효과를 평가하기 위해 실험예 1에서와 동일 세포를 사용하여 동일 조건으로 실험을 진행하였다. 단지 최종적으로 실시간 중합효소 연쇄반옹을 진행하는 과정에서 MMP-1 주형을 대신하여 ΙΙβ -HSDl 주형을 사용하였다. 주형의 서열과 반웅 조건은 상기의 표 1과 같았으며, 유전자의 발현량은 β -act in 유전자에 대한 보정을 통해 최종적으로 분석하였다. 이에 대한결과는도 2에 나타내었다.
Figure imgf000007_0001
As a result, as shown in FIG. 1, MMP-1 expression was increased in the UVB irradiation group, whereas MMP-1 gene expression was decreased in a concentration-dependent manner in the sperm extract treatment group. Experimental Example 2: Evaluation of ΙΙ β -HSDl Inhibitory Activity of Copper Palatinum Extract In order to evaluate the ΙΙβ -HSDl inhibitory effect of the sperm extract of Example 1, the experiment was conducted under the same conditions using the same cells as in Experimental Example 1. Finally, in the process of real-time polymerase chain reaction, Ιβ-HSDl template was used instead of MMP-1 template. The sequence and reaction conditions of the template were as shown in Table 1 above, and the expression level of the gene was finally analyzed through correction for β-act in gene. The results are shown in FIG. 2.
그 결과, 도면 2에 나타낸 바와 같이 동규자 추출물 처리군에서 MMP-1 유전자 발현량과 마찬가지로 농도 의존적으로 ΙΙβ -HSDl 유전자 발현량이 감소함을 확인하였다. 실험예 3: 인공배양피부에서 동규자추출물의 MMP-1 저해능 평가  As a result, as shown in Fig. 2, it was confirmed that the expression level of ΙΙβ -HSDl gene was decreased in concentration-dependent manner in the sperm extract treatment group as in the MMP-1 gene expression amount. Experimental Example 3: Evaluation of MMP-1 Inhibitory Activity of Copper Palatinum Extract in Artificial Culture Skin
실시예 1의 동규자 추출물의 MMP-1 저해 효과를 조직수준에서 평가하기 위해 삼차원 인공배양피부 조직인 EpiDermFTTM(MatTek, 미국)을 이용한 실험을 진행하였다. In order to evaluate the MMP-1 inhibitory effect of the sperm extract of Example 1 at the tissue level, an experiment was performed using EpiDermFT (MatTek, USA), which is a three-dimensional artificial cultured skin tissue.
표피-진피를 모두 포함하는 EpiDermFT™을 1차적으로 배양 배지에 24시간 동안 안정화시킨 후 배지를 제거하고 UVB 비조사군을 제외한 나머지 실험군에 60 mJ/cm2의 UVB를 조사한 뒤 동규자 추출물을 농도별로 첨가한 배지로 교체하여 48시간 동안 추가로 배양하였다. 이후 인공피부 조직을 배양한 배지를 수거하여 원심분리로 부유물을 제거하여 배지 내에 포함된 단백질의 양을 측정하는 데 사용하였다. 배양 배지 내에 포함된 MMP-1 단백질 양은 MMP-1 ELISA Ki t (EMD Mi l l ipore , 미국)를 이용하여 안내된 방법으로 측정하였다. EpiDermFT ™ containing both epidermis and dermis was first stabilized in the culture medium for 24 hours, and then the medium was removed, and 60 mJ / cm 2 of UVB was irradiated to the remaining experimental groups except for the non-UVB irradiated group, and sperm extract was added by concentration Alternate with one medium and incubate further for 48 hours. Then, the culture medium obtained by culturing artificial skin tissue was collected and used to measure the amount of protein contained in the medium by removing suspended solids by centrifugation. The amount of MMP-1 protein contained in the culture medium was measured by the guided method using MMP-1 ELISA Ki t (EMD Mill ipore, USA).
그 결과, 도면 3에 나타낸 바와 같이 UVB 조사군의 배양 배지 내 MMP-1 함량이 비조사군에 비해 높은 것에 반해, 동규자 추출물 처리군에서는 비조사군과 같은수준으로 MMP-1 함량이 감소함을 확인하였다. 실험예 4: 인공배양피부에서 동규자 추출물의 procol lagen type I증가능 실시예 1의 동규자 추출물의 procol lagen type I 증가 효과를 조직수준에서 평가하기 위해 실험예 3에서와 동일 조직을 사용하여 동일 조건으로 실험을 진행하였다. 단지 최종적으로 배양 배지 내의 procol lagen type I 함량을 측정하는 과정에서 Procol lagen type I C-pept ide (PIP) EIA ki t (Takara-bio Inc . , 일본)를사용하여 안내된 방법으로 측정하였다. As a result, as shown in FIG. 3, the MMP-1 content in the culture medium of the UVB irradiated group was higher than that of the unirradiated group, whereas the MMP-1 content was decreased in the same group as the unirradiated group. . Experimental Example 4: Procol lagen type I could be increased by sperm extract in artificial culture skin. The experiment was carried out under the conditions. Finally, the procol lagen type I content in the culture medium was measured by a guided method using Procol lagen type I C-peptide (PIP) EIA kit (Takara-bio Inc., Japan).
그 결과, 도면 4에 나타낸 바와 같이 UVB 조사군의 배양 배지 내 procol lagen type I 함량이 비조사군에 비해 적은 것에 반해, 동규자 추출물을 처리군에서는 그함량이 증가하는 것을 확인하였다. 제형예 1: 토너제의 제조  As a result, as shown in FIG. 4, the content of procol lagen type I in the culture medium of the UVB irradiated group was lower than that of the non-irradiated group. Formulation Example 1 Preparation of Toner
상기 실시예 1에서 얻은 추출물을 함유하는 토너제를 하기의 표 2에 나타낸 조성성분 및 조성비에 따라통상적인 방법으로 제조하였다.  The toner agent containing the extract obtained in Example 1 was prepared in the usual manner according to the composition components and composition ratios shown in Table 2 below.
【표 2] [Table 2]
Figure imgf000009_0001
제형예 2: 로션제의 제조
Figure imgf000009_0001
Formulation Example 2: Preparation of Lotion
상기 실시예 1에서 얻은 추출물을 함유하는 로션제를 하기의  The lotion containing the extract obtained in Example 1 below
나타낸 조성성분 및 조성비에 따라통상적인 방법으로 제조하였다. It was prepared by the usual method according to the composition components and composition ratios shown.
【표 3】 Table 3
성분 함량 (중량 %)  Ingredient Content (% by weight)
실시예 1 1 .0  Example 1 1.0
글리세린 7.0  Glycerin 7.0
부릴렌글라이콜 3.0  Burylene Glycol 3.0
글리세릴스테아레이트 /피이지 -100스테아레이트 1 .0  Glyceryl Stearate / Fiji -100 Stearate 1.0
플리소르베이트 60 0.5  Plysorbate 60 0.5
소르비탄세스퀴올리에이트 0.5  Sorbitan Sesquioleate 0.5
스쿠알란 3.0  Squalane 3.0
카프릴릭 /카프릭 트리글리세라이드 5.0 쉐어버터 2.0 Caprylic / Capric Triglycerides 5.0 Shea Butter 2.0
스테아릴 알코올 0.5  Stearyl Alcohol 0.5
스테아린산 0.5  Stearic Acid 0.5
카르복실비닐풀리머 0.2  Carboxyl Vinyl Puller 0.2
아르기닌 0.2  Arginine 0.2
방부제 미량 향료 미량 정제수 잔량 제형예 3: 크림제의 제조  Preservative trace fragrance trace Purified water residual amount Formulation example 3: Preparation of cream
상기 실시예 1에서 얻은 추출물을 함유하는 크림제를 하기의 나타난조성성분 및 조성비에 따라통상적인 방법으로 제조하였다.  Cream containing the extract obtained in Example 1 was prepared according to the conventional method according to the composition and composition ratio shown below.
【표 4】 Table 4
Figure imgf000010_0001
참조문헌
Figure imgf000010_0001
Reference
(특허문헌 0001) KR 10-0825256 B  (Patent Document 0001) KR 10-0825256 B
(특허문헌 0002) KR 10-1393007 B (Patent Document 0002) KR 10-1393007 B

Claims

【청구의 범위】 [Range of request]
【청구항 1】 [Claim 1]
동규자 추출물을 유효성분으로 함유하는 피부노화 또는 주름 개선용 화장료조성물.  A cosmetic composition for improving skin aging or wrinkles, which contains an extract of Donggyuja as an active ingredient.
【청구항 2] [Claim 2]
제 1항에 있어서, 상기 동규자 추출물은 물, 무수 또는 함수의 메탄을, 에탄올, 프로필 알코을, 부틸 알코을, 글리세린, 프로필렌 글리콜, 부틸렌 글리콜, 또는 이들의 흔합용매로 구성된 군으로부터 선택된 하나 이상의 용매로 추출된 것을 특징으로 하는 피부노화또는주름 개선용 화장료조성물.  The method of claim 1, wherein the sperm extract is water, anhydrous or hydrous methane, at least one solvent selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, glycerin, propylene glycol, butylene glycol, or a mixed solvent thereof Cosmetic composition for improving skin aging or wrinkles, characterized in that extracted.
【청구항 3】 [Claim 3]
제 1항에 있어서, 상기 동규자 추출물은 조성물 총 중량 대비 0.01 내지 50 중량 % 포함하는 것을 특징으로 하는 피부노화 또는 주름 개선용 화장료 조성물.  The cosmetic composition for aging or wrinkle improvement according to claim 1, wherein the sperm extract comprises 0.01 to 50% by weight, based on the total weight of the composition.
【청구항 4】 [Claim 4]
제 1항에 있어서, 상기 동규자 추출물은 llp -HSDl(ll]3 -hydroxysteroid dehydrogenase type 1)을 억제함으로써 피부노화개선 효과를 나타내는 것을 특징으로 하는 피부노화또는주름 개선용 화장료조성물.  The method of claim 1, wherein the extract is a cosmetic composition for improving skin aging or wrinkles by inhibiting llp -HSDl (ll) 3 -hydroxysteroid dehydrogenase type 1).
【청구항 5] [Claim 5]
제 1항에 있어서, 상기 동규자 추출물은 MMP-l(Matr ix metal loproteinase- 1)을 억제함으로씨 주름 개선 효과를 나타내는 것을 특징으로 하는 피부노화 또는주름 개선용화장료조성물.  The composition of claim 1, wherein the extract of Donggyuja exhibits an effect of improving seed wrinkles by inhibiting MMP-1 (Matr ix metal loproteinase-1).
【청구항 6】 [Claim 6]
제 1항에 있어서, 상기 동규자 추출물은 procol lagen type I의 발현을 증가시킴으로써 피부노화 또는 주름개선 효과를 나타내는 것을 특징으로 하는 피부노화 또는 주름개선용 화장료 조성물. According to claim 1, wherein the sperm extract extracts the expression of procol lagen type I Skin aging or wrinkle improvement cosmetic composition, characterized in that by increasing the skin aging or wrinkle improvement effect.
【청구항 7】 [Claim 7]
제 1항에 있어서, 상기 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징품, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 구성된 제형에서 선택된 하나 이상의 제형인 것을 특징으로 하는 피부노화 또는 주름 개선용 화장료 조성물.  According to claim 1, wherein the composition is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, Cosmetic composition for skin aging or wrinkle improvement, characterized in that at least one formulation selected from the pack, soap, cleansing products, cleansing lotion, cleansing cream, body lotion and body cleanser.
PCT/KR2016/006358 2015-07-06 2016-06-15 Cosmetic composition for alleviating skin aging or skin wrinkles, containing malva verticillata seed extract WO2017007142A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150096012A KR101762111B1 (en) 2015-07-06 2015-07-06 Cosmetic composition comprising Malva verticillata Seed extract for prevention of skin aging or anti-wrinkles
KR10-2015-0096012 2015-07-06

Publications (1)

Publication Number Publication Date
WO2017007142A1 true WO2017007142A1 (en) 2017-01-12

Family

ID=57685684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/006358 WO2017007142A1 (en) 2015-07-06 2016-06-15 Cosmetic composition for alleviating skin aging or skin wrinkles, containing malva verticillata seed extract

Country Status (2)

Country Link
KR (1) KR101762111B1 (en)
WO (1) WO2017007142A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094073B1 (en) 2018-05-11 2020-03-26 대구한의대학교산학협력단 Cosmetic composition for improving anti-wrinkle effect comprising the extract of Heugseol
KR102491505B1 (en) * 2021-06-07 2023-01-26 주식회사 코리아나화장품 Cosmetic Composition For Preventing Hair Loss Containing Fatty acids isolated from Malva verticillata L. Seed Extract

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0959127A (en) * 1995-08-10 1997-03-04 Mikimoto Pharmaceut Co Ltd Food product and cosmetic containing solvent extract from malva verticillata
JP2005008539A (en) * 2003-06-17 2005-01-13 Fancl Corp Matrix metalloproteinase inhibitor
WO2005011606A2 (en) * 2003-07-31 2005-02-10 Light Bioscience, Llc System and method for the photodynamic treatment of burns, wounds, and related skin disorders
KR20130058132A (en) * 2011-11-25 2013-06-04 (주)아모레퍼시픽 Cosmetic composition containing hibiscus abelmoschus extracts or birch sap for skin homeostasis and anti-aging
WO2013091684A1 (en) * 2011-12-20 2013-06-27 Oriflame Research And Development Ltd. Compounds with anti-aging activities
WO2014158671A1 (en) * 2013-03-14 2014-10-02 Avon Products, Inc Abutilon indicum extracts and methods of use
JP2014224081A (en) * 2013-05-14 2014-12-04 香栄興業株式会社 Composition containing plant placenta extracts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100825256B1 (en) 2006-10-23 2008-05-26 재단법인 제주하이테크산업진흥원 Cosmetic compositions for prevention of skin aging and anti-wrinkles containing extract of Cassia mimosoides var. nomame
KR101393007B1 (en) 2007-11-30 2014-05-13 주식회사 코리아나화장품 Cosmetic Composition for Skin-aging Protection and Wrinkle Improvement Comprising the Extract of Nephelium lappaceum and Litchi chinensis sonn as Active Ingredient

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0959127A (en) * 1995-08-10 1997-03-04 Mikimoto Pharmaceut Co Ltd Food product and cosmetic containing solvent extract from malva verticillata
JP2005008539A (en) * 2003-06-17 2005-01-13 Fancl Corp Matrix metalloproteinase inhibitor
WO2005011606A2 (en) * 2003-07-31 2005-02-10 Light Bioscience, Llc System and method for the photodynamic treatment of burns, wounds, and related skin disorders
KR20130058132A (en) * 2011-11-25 2013-06-04 (주)아모레퍼시픽 Cosmetic composition containing hibiscus abelmoschus extracts or birch sap for skin homeostasis and anti-aging
WO2013091684A1 (en) * 2011-12-20 2013-06-27 Oriflame Research And Development Ltd. Compounds with anti-aging activities
WO2014158671A1 (en) * 2013-03-14 2014-10-02 Avon Products, Inc Abutilon indicum extracts and methods of use
JP2014224081A (en) * 2013-05-14 2014-12-04 香栄興業株式会社 Composition containing plant placenta extracts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG, JAE GI ET AL.: "A Study on Skin Aging Caused by Free-Radical and on Efficacy of Antioxidant Vitamins", JOURNAL OF JOURNAL OF KOREAN SOCIETY FOR AESTHETICS AND COSMETOLOGY, vol. 7, no. 2, 2009, pages 51 - 62 *
SYED, DEEBA N. ET AL.: "Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities", ANTICANCER AGENTS MED. CHEM, vol. 13, no. 8, October 2013 (2013-10-01), pages 1149 - 1161 *

Also Published As

Publication number Publication date
KR101762111B1 (en) 2017-07-28
KR20170005952A (en) 2017-01-17

Similar Documents

Publication Publication Date Title
TWI515019B (en) Use of tiliacora triandra in cosmetics and compositions thereof
JP2010514774A (en) Composition for improving skin condition and appearance and method of use thereof
JP2003300858A (en) Skin care preparation
JPH06128138A (en) Cosmetic
JP2006241148A (en) Collagenase inhibitor and external preparation for skin for preventing aging
WO2017007142A1 (en) Cosmetic composition for alleviating skin aging or skin wrinkles, containing malva verticillata seed extract
CN114423400B (en) Cosmetic composition containing graphene quantum dots as active ingredient
JP2001302439A (en) Cosmetic comprising extract extracted from prenus persia batsh
KR101835039B1 (en) Cosmetic composition for improving melasma comprising herbal extract
CN110840785B (en) Cosmetic composition for improving skin aging or skin wrinkles
JP5366358B2 (en) Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method
TWI687237B (en) Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin
JP4675770B2 (en) Agent for reducing TGF-β receptor production by ultraviolet rays
JP5000964B2 (en) Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression
JP2002284648A (en) Composition for hair restorer
JP4689215B2 (en) Moisturizer, cell activator, whitening agent, and collagenase inhibitor
JP5155543B2 (en) Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method
JP5171752B2 (en) Topical skin preparation
JP6589244B2 (en) Skin preparation
JP6843537B2 (en) Anti-skin aging agent and topical cosmetics containing it
JP7485336B2 (en) MSX-2 mRNA expression promoter, eyelash growth agent, and external preparation composition for eyelash growth
JP7411196B2 (en) Type XVII collagen maintenance and enhancement agent
JP2018108973A (en) Type xvii collagen production promoter
KR20110101727A (en) Composition for improving skin wrinkle
WO2022092124A1 (en) Matrix metalloprotease 1 expression inhibitor, skin external agent, and use for inhibition of matrix metalloprotease 1 expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16821548

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16821548

Country of ref document: EP

Kind code of ref document: A1